Systems toxicology: modelling biomarkers of glutathione homeostasis and paracetamol metabolism

详细信息    查看全文

• 作者：Simone H. Stahl¹ ; James W. Yates² ; Andrew W. Nicholls³ ; J. Gerry Kenna⁴ ; Muireann Coen⁵ ; Fernando Ortega⁶ ; Jeremy K. Nicholson⁵ ; Ian D. Wilson⁵ ; ^{i.wilson@imperial.ac.uk" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Drug Discovery Today: Technologies
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：15
• 期：Complete
• 页码：9-14
• 全文大小：485 K

文摘

One aim of systems toxicology is to deliver mechanistic, mathematically rigorous, models integrating biochemical and pharmacological processes that result in toxicity to enhance the assessment of the risk posed to humans by drugs and other xenobiotics. The benefits of such ‘in silico’ models would be in enabling the rapid and robust prediction of the effects of compounds over a range of exposures, improving in vitro–in vivo correlations and the translation from preclinical species to humans. Systems toxicology models of organ toxicities that result in high attrition rates during drug discovery and development, or post-marketing withdrawals (e.g., drug-induced liver injury (DILI)) should facilitate the discovery of safe new drugs. Here, systems toxicology as applied to the effects of paracetamol (acetaminophen, N-acetyl-para-aminophenol (APAP)) is used to exemplify the potential of the approach.